Special 125th Anniversary Issue – Bulletin

strategic core competencies in place, the AAO HNS/F rapidly embarked on the development, launch, and implementation of its clinical data registry, Reg-ent. The subspecialty registry moved quickly from the business planning stage through to Board approval and then obtained approval from the Centers for Medicare & Medicaid to operate as a Qualified Clinical Data Registry, a status that has been maintained since 2016. Year over year member participation continues to increase in Reg-ent particularly as regulatory reporting burdens grow. Reg-ent is diversifying its offerings and preparing for the next phases of registry development as the clinical data in Reg-ent increased exponentially. In 2019 it expanded its capabilities into research and data analytics for the benefit of all members regardless of practice setting. By 2019 Reg-ent participants were accessing their data to optimize subspecialty measures and collaborating with others via the annual Reg-ent Users Conference at the AAO-HNSF Annual Meeting & OTO Experience. The ultimate goal of Reg-ent is to harness data for impactful research to ensure quality care, evidence based practice, and outstanding patient outcomes in otolaryngology-head and neck surgery. Reg-ent sets the stage for our members in supporting clinical investigation and pre- and post-market surveillance of devices and drugs, as well as easing the process for participation in clinical trials. By investing early in the development of the infrastructure required to produce and

(MVP) program is designed to include sets of measurement options that are more relevant to a physician’s scope of practice and more meaningful to patient care. We are developing clinical pathways that emulate the way our members see patients and include outcome oriented measures. We will be submitting potential MVP projects involving hearing loss, chronic rhinosinusitis, and early oral cavity cancer in 2021 with the intention to have similar opportunities available in all specialty areas. Through this work we will maintain our role in defining quality for the specialty and ensuring appropriate reimbursement for the services rendered.

publish quality related knowledge products (clinical practice guidelines, clinical consensus statements, quality measures), we set the stage to expand into all areas required to measure and demonstrate high quality healthcare. Our clinical data registry is set up to allow measurement of a wide range of clinical problems and to participate in both prospective and retrospective clinical trials. We are beginning the next phase along the registry continuum as we partner with OM1, who adds analytic capabilities and access to additional data sources that will provide increased flexibility as we move toward value-based care. The MIPS Value Pathways

31

ENTNET.ORG/BULLETIN AAO-HNS BULLETIN SPECIAL EDITION: 125TH ANNIVERSARY